GlassScriptPhysician profile
Beth Gruzinskas
NPI 1942699988
$3,761.40
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,985 · 2022: $1,579 · 2023: $162 · 2024: $35.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $410.50 | 2021-2022 | |
| Janssen Biotech, INC. | $368.74 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $254.63 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $204.44 | 2021-2022 | |
| Incyte Corporation | $192.04 | 2021-2022 | |
| Eisai INC. | $158.72 | 2021-2022 | |
| Daiichi Sankyo INC. | $157.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $155.42 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $152.25 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $141.99 | 2021-2022 | |
| Beigene USA, INC. | $110.01 | 2021-2023 | Brukinsa |
| Karyopharm Therapeutics INC. | $97.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.76 | 2021-2022 | |
| Lilly USA, LLC | $76.27 | 2021-2022 | |
| Morphosys, US INC. | $68.86 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Gruzinskas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.